Within this study population, the impact on laboratory parameters was modest and not significant by 1 year. The small changes may reflect already good medical management. By design, ICAN participants had health insurance. All were taking diabetes medications, and most were on antihypertensive (76%) and cardiovascular medications (64%). Average baseline values of HbA^sub 1c^ and lipid levels suggested generally good control. Despite such control, a modest-cost lifestyle intervention helped maintain lower HbA^sub 1c^ levels. Future interventions should consider baseline values in determining the intensity of the intervention. Additionally, as we begin to translate efficacy to practice, different criteria will be needed to define "success." Instead of the magnitude of effect solely defining success, the reach, effectiveness, adoption, implementation, and maintenance of the program (RE-AIM) must be addressed